Emergent Biosolutions, Inc. (NYSE:EBS) Chairman Fuad El-Hibri sold 16,439 shares of the business’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $37.50, for a total transaction of $616,462.50. Following the transaction, the chairman now owns 1,605,216 shares in the company, valued at approximately $60,195,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Fuad El-Hibri also recently made the following trade(s):

  • On Tuesday, September 5th, Fuad El-Hibri sold 3,100 shares of Emergent Biosolutions stock. The shares were sold at an average price of $37.50, for a total transaction of $116,250.00.
  • On Thursday, August 31st, Fuad El-Hibri sold 5,461 shares of Emergent Biosolutions stock. The shares were sold at an average price of $37.50, for a total transaction of $204,787.50.
  • On Thursday, July 27th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $36.50, for a total transaction of $912,500.00.
  • On Thursday, July 20th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The shares were sold at an average price of $35.50, for a total transaction of $887,500.00.

Emergent Biosolutions, Inc. (NYSE EBS) traded up 0.16% on Friday, reaching $37.64. 207,981 shares of the company’s stock were exchanged. The firm has a market cap of $1.55 billion, a PE ratio of 23.97 and a beta of 1.23. Emergent Biosolutions, Inc. has a one year low of $24.47 and a one year high of $37.98. The firm has a 50 day moving average price of $35.84 and a 200 day moving average price of $32.27.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.26 by $0.13. The firm had revenue of $100.77 million during the quarter, compared to analyst estimates of $111.57 million. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The business’s revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.05) earnings per share. On average, equities analysts anticipate that Emergent Biosolutions, Inc. will post $1.54 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Emergent Biosolutions, Inc. (EBS) Chairman Fuad El-Hibri Sells 16,439 Shares” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/08/emergent-biosolutions-inc-ebs-chairman-fuad-el-hibri-sells-16439-shares.html.

A number of research analysts have weighed in on the stock. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Friday, August 25th. Zacks Investment Research cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Emergent Biosolutions presently has an average rating of “Buy” and a consensus target price of $44.00.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Riverhead Capital Management LLC grew its position in Emergent Biosolutions by 102.8% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,542 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in Emergent Biosolutions by 23.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 587 shares in the last quarter. State of Alaska Department of Revenue grew its position in Emergent Biosolutions by 2.7% in the 1st quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 100 shares in the last quarter. Creative Planning grew its position in Emergent Biosolutions by 1.2% in the 2nd quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 55 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its position in Emergent Biosolutions by 17.3% in the 1st quarter. Envestnet Asset Management Inc. now owns 5,710 shares of the biopharmaceutical company’s stock valued at $165,000 after acquiring an additional 844 shares in the last quarter. 85.44% of the stock is owned by institutional investors.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.